Improving and Accelerating Drug Development for Nervous System Disorders
نویسندگان
چکیده
منابع مشابه
Improving and Accelerating Drug Development for Nervous System Disorders
Advances in the neurosciences have placed the field in the position where it is poised to significantly reduce the burden of nervous system disorders. However, drug discovery, development, and translation for nervous system disorders still pose many unique challenges. The key scientific challenges can be summarized as follows: mechanisms of disease, target identification and validation, predict...
متن کاملDrug-induced disorders of the nervous system.
J Dtsch Dermatol Ges 2006;4:308–18. In German. 19 Mahmud E, Brocato M, Palakodeti V, Tsimikas S. Fibromuscular dysplasia of renal arteries: percutaneous revascularization based on hemodynamic assessment with a pressure measurement guidewire. Catheter Cardiovasc Interv 2006;67:434–7. 20 Laforet P, Eymard B. [Exercise-intolerance and exercise-induced rhabdomyolysis: etiology and diagnosis.] Revie...
متن کاملCentral nervous system biomarkers for antiobesity drug development☆
With antiobesity agents, weight loss can emerge from an array of metabolic, cognitive and behavioural changes that translate into weight change over time. In early drug development, characterising these changes can actually be more informative than simply measuring weight loss. Biomarkers for these mechanisms can be used to determine whether potential compounds are worth developing further by p...
متن کاملIon Channels as Drug Targets in Central Nervous System Disorders
Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system. Within the CNS, basic indications of drugs are: sleep disorders, anxiety, epilepsy, pain, etc. However, traditional channel blockers have multiple adverse events, mainly due to low specificity of mechanism of action. Lately, novel ion cha...
متن کاملAccelerating Drug Discovery and Development Using Genomics
Despite the continuing advancements in the treatment of cancer and the introduction of new therapies, responses still vary from patient to patient. In many cases, this variation remains unexplained, making it difficult to predict who will respond. For instance, immunotherapies targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and the PD-1 li...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuron
سال: 2014
ISSN: 0896-6273
DOI: 10.1016/j.neuron.2014.10.007